CASE REPORT

Symptomatic Improvement of Diffuse Esophageal Spasm after Botulinum Toxin Injection

Jae Pil Han, Su Jin Hong, Hoon Il Kim, Jin Myung Byun, Hwa Jong Kim, Bong Min Ko, Joon Seong Lee and Moon Sung Lee
Department of Internal Medicine, Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea

Diffuse esophageal spasm, an uncommon esophageal motility disorder, has recently been defined using high-resolution manometry. Patients with distal esophageal spasm usually complain of chest pain or dysphagia. The etiology and pathophysiology of this disorder are poorly known, and treatment options are limited. However, some options to improve symptoms are available, including endoscopic injection of botulinum toxin. Nevertheless, few reports have described the effects of endoscopic injection of botulinum toxin in patients with symptomatic diffuse esophageal spasm with clear endoscopic and high-resolution manometry images. Here, we report a case of diffuse esophageal spasm diagnosed with high-resolution manometry and treated by endoscopic injection of botulinum toxin with good results at the 7-month follow-up. (Korean J Gastroenterol 2012;60:109-112)

Key Words: Diffuse esophageal spasm; Botulinum toxins; Manometry

INTRODUCTION

Esophageal spasm (ES) is a rare esophageal motility disorder characterized by simultaneous esophageal contraction with intermittent peristalsis on conventional manometry.1 Although the pathophysiology and etiology remain uncertain, the suggested pathophysiology of ES includes cholinergic, nitregic, and reflux mechanisms.2 Patients with ES usually complain of dysphagia or chest pain, which are difficult to distinguish from angina pectoris. Many trials have reported the efficacy of pharmacological, endoscopic, and surgical therapies. Recent studies suggest a benefit of injecting botulinum toxin in the diffuse esophagus for treating symptomatic ES.3 We report a case of a 69-year-old woman with manometrically proven symptomatic ES treated with intramuscular injection of botulinum toxin.

CASE REPORT

A 69-year-old woman with dysphagia and excessive vomiting was admitted to our hospital. She felt chest discomfort while swallowing solid or liquid food for several months. She was taking antihypertensive medicine and had a history of bronchial asthma. Radiographic examinations were done to rule out underlying diseases. There was no active lesion in her chest x-ray or on chest CT. The esophagogram showed repetitive, multifocal, and simultaneous contractions in the esophageal body (Fig. 1A). She had no evidence of cardiac disease on electrocardiography. Esophagogastroduodenoscopy showed strong, repetitive contractions in the lower...
The initial esophagogram showed repetitive, multifocal, and simultaneous contraction in the esophageal body. (B) Initial esophagoscopy showed much impacted food in the esophageal lumen, which was not dilated fully during the observations. There was no stricture in the esophageal body or at the esophagogastric junction.

High-resolution manometry showed rapid contractile front velocity (CFV) attributed to spasm throughout the distal esophageal segments.

The esophagogram 3 months after botulinum toxin injection showed decreased tertiary movement in the distal esophageal segments and smooth passage of barium through the distal esophagus and gastroesophageal junction without stasis. (B) Follow-up esophagoscopy 14 days after botulinum toxin injection showed no food in the esophageal lumen. The esophageal lumen was relatively dilated compared with before treatment.

No obstructive lesion was detected in the esophagus on endoscopy. High-resolution manometry (HRM, ManoScan ver. 2.0.1; Sierra Scientific Instruments, Los Angeles, CA, USA) with 36 solid-state sensors spaced at 1-cm intervals was performed to assess the esophageal motility. This showed swallows with rapid contractile front velocity (CFV) attributable to spasm. Five of ten swallows revealed rapid CFV, which corresponded to diffuse ES (DES). In addition, the swallows frequently showed high amplitude in the esophageal body. On HRM, the lower esophageal sphincter (LES) was relaxed following swallows (Fig. 2). The patient was diagnosed with DES based on the clinical symptoms and radiological and manometric findings. We injected botulinum toxin endoscopically to treat her symptoms. Botulinum toxin 100 IU (Botox®; Allergan Korea Ltd., Seoul, Korea) was diluted in 10 mL of normal saline (NaCl 0.9%) and injected in the contraction ring of the lower esophagus at ten levels at 10-mm intervals. The next day, her DES symptoms were reduced substantially, and the patient could swallow liquid and solid food. Subsequently, the patient has not complained of severe symptoms caused by DES. Her clinical symptoms (chest pain, dysphagia, and regurgitation) were measured before and after treatment using an analogue scale (0=no symptoms, 1=occasional, 2=daily, 3=constant). The total symptom score improved from 8 before treatment to 3 (1 each for chest pain, dysphagia, and regurgitation) after 7 days. The patient was discharged without complications. Follow-up esophagoscopy 14 days after the botulinum injection did not show food in the esophageal lumen or strong repetitive contractions (Fig. 3B). After 3 months, the follow-up esophagogram showed significantly decreased tertiary contractions in the mid to distal esophagus, and contrast passed through the gastroesophageal junction smoothly without stasis (Fig. 3A). The clinical response was maintained for over 7 months with an improved total symptom score.
DISCUSSION

DES is a rare esophageal motility disorder found in patients with unexplained chest pain or dysphagia, accounting for about 3% of the motility abnormalities seen in such patients.1 In Korea, DES is diagnosed in 0.9-2.2% of the patients with esophageal symptoms.4,6 Chest pain (46-47%) and dysphagia (27-41%) are the primary presenting symptoms in this population.9 Some patients complain of globus (9-11%), acid regurgitation (9%), and indigestion (9%).7 Non-cardiac chest pain is often difficult to differentiate from cardiac angina, but the chest pain caused by the esophagus is non-radiating, is relieved by swallowing water, and is triggered by swallowing a large amount of solid or liquid food. Although the mechanisms of non-cardiac chest pain are uncertain, some have been suggested, including the presence of acid reflux, esophageal motility abnormalities, and visceral hypersensitivity.8,9 Dysphagia for both liquid and solids occurs intermittently and is rarely progressive. The degree of dysphagia varies, and it is not always accompanied by chest pain. In this case, the patient’s chief complaints were dysphagia, vomiting, and non-cardiac chest pain.

The pathogenesis of DES is unclear, but studies suggest altered endogenous nitric oxide (NO) synthesis or degradation.3 Many animal and human studies have suggested that NO plays an important role in maintaining esophageal peristalsis. Based on this mechanism, there are reports on the effects of nitroglycerine and long-acting nitrates in patients with DES.10

Contrast esophagography in DES patients may reveal delayed passage or a “cork screw” appearance due to prominent tertiary waves, but these are non-specific. Esophageal manometry is considered the gold standard for diagnosing DES, and the hallmark is simultaneous contractions (>20% wet swallows) with intermittent peristalsis. Other abnormal manometric findings include repetitive contraction (>3 peaks), prolonged contraction, retrograde contraction, and isolated incomplete LES relaxation.7,11,12 Conventional manometry has some limitations for assessing esophageal motility. HRM with 36 solid-state sensors spaced at 1-cm intervals has several advantages over conventional manometry and is used widely. The Chicago classification was developed to analyze esophageal motility using HRM data for 75 control subjects and 400 consecutive patients.12,13 This classification has been modified as the Chicago classification (c2/2009) of distal esophageal motility disorders to improve its clinical usefulness and accuracy. The HRM Classification Working Group proposed an analysis algorithm using pressure topography parameters. First, patients are characterized by esophagogastric junction (EGJ) pressure morphology (presence of hiatus hernia) and the presence or absence of impaired deglutitive EGJ relaxation. Second, each swallow is further categorized by the characteristics of the distal esophageal contraction. Finally, the results of HRM are interpreted using the Chicago classification of distal esophageal motility disorders.14 DES has normal EGJ relaxation (a mean integrated relaxation pressure [IRP] <15 mmHg) and normal intrabolus pressure (IBP), and it is characterized by spasm (CFV > 8 cm/sec) in ≥20% of swallows. Although this new methodology is useful for evaluating esophageal motor function, more studies are required to refine the diagnostic criteria and resolve uncertain issues. In our case, the 69-year-old woman was diagnosed with DES based on her clinical symptoms and radiological and HRM findings.

Therapy for symptomatic DES has included medical approaches and surgical intervention. As acid reflux has been suggested as the mechanism of esophageal contractions, empirical trial with proton pump inhibitor (PPI) can be recommended initially. Agents such as anticholinergics, nitrates, calcium channel blockers, and antidepressants can be used for patients with inadequate response to PPI.15,16 Although medical treatment can reduce the symptoms of DES, there have been no large double-blind trials of these agents. Other methods of treating DES, including pneumatic dilatation and surgical myotomy, have been used in patients with severe DES.17,18 However, these interventions have a relatively high risk of complications, such as esophageal perforation.17 Endoscopic injection of botulinum toxin into the LES is effective in the treatment of achalasia.19 This method also showed good results in patients with severe DES. The symptoms in DES patients, which resist medical treatment, improved significantly after the endoscopic injection of botulinum toxin into the esophageal muscle, and the clinical response persisted for at least 6 to 12 months. Some patients with relapsed symptoms underwent repeated injection of botulinum toxin and were successfully retreated.3 No further side effects have been reported in patients with achalasia or DES.
treated with botulinum toxin injection. In the present case, we injected botulinum toxin endoscopically to treat symptomatic DES. After the injection, the esophageal symptoms were relieved, and the clinical response continued for over 7 months without repeated injection of botulinum.

REFERENCES